Pfizer Zavicefta (Outside the U.S. and Canada) — Revenues: decreased by 17.1% to $150.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 11.1%, from $135.00M to $150.00M. Over 4 years (FY 2021 to FY 2025), Zavicefta (Outside the U.S. and Canada) — Revenues: shows an upward trend with a 11.5% CAGR.
pfe_segment_zavicefta_outside_the_u_s_and_canada_revenues| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $104.00M | $107.00M | $107.00M | $104.00M | $100.00M | $98.00M | $110.00M | $116.00M | $132.00M | $130.00M | $133.00M | $125.00M | $150.00M | $152.00M | $159.00M | $135.00M | $163.00M | $158.00M | $181.00M | $150.00M |
| QoQ Change | — | +2.9% | +0.0% | -2.8% | -3.8% | -2.0% | +12.2% | +5.5% | +13.8% | -1.5% | +2.3% | -6.0% | +20.0% | +1.3% | +4.6% | -15.1% | +20.7% | -3.1% | +14.6% | -17.1% |
| YoY Change | — | — | — | — | -3.8% | -8.4% | +2.8% | +11.5% | +32.0% | +32.7% | +20.9% | +7.8% | +13.6% | +16.9% | +19.5% | +8.0% | +8.7% | +3.9% | +13.8% | +11.1% |